Skip to main content
SpringerLink
Log in

Treatment of PCOS with metformin and other insulin-sensitizing agents

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

A significant proportion of women with polycystic ovary syndrome (PCOS) suffer from insulin resistance and compensatory hyperinsulinemia. Growing evidence indicates that elevated serum insulin induces hyperandrogenism, which in turn leads to anovulation and infertility. Hyperinsulinemia also contributes to the increased risk for cardiovascular disorders and type 2 diabetes mellitus. These concepts provide a rationale for therapies focused on treatments of insulin resistance. Metformin is the most extensively studied insulin-sensitizing agent for the treatment of women with PCOS. Use of metformin leads to a decrease in serum insulin and androgen levels, as well as an improvement in ovulatory function. Other insulin-sensitizing agents studied in women with PCOS include troglitazone, rosiglitazone, pioglitazone, and D-chiro-inositol.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Stein IF, Leventhal ML: Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935, 29:181–191.

    Google Scholar 

  2. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al.: Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998, 83:3078–3082.

    Article  PubMed  CAS  Google Scholar 

  3. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al.: A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999, 84:4006–4011.

    Article  PubMed  CAS  Google Scholar 

  4. Asuncion M, Calvo RM, San Millan JL, et al.: A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000, 85:2434–2438.

    Article  PubMed  CAS  Google Scholar 

  5. Hull MGR: Epidemiology of infertility and polycystic ovarian disease: endocrinologic and demographic studies. Gynecol Endocrinol 1987, 1:235–245.

    PubMed  CAS  Google Scholar 

  6. Adams J, Polson DW, Franks S: Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 1986, 293:355–359.

    Article  CAS  Google Scholar 

  7. Dunaif A, Graf M, Mandeli J, et al.: Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987, 65:499–507.

    PubMed  CAS  Google Scholar 

  8. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective controlled study in 254 affected women. J Clin Endocrinol Metab 1999, 84:165–169.

    Article  PubMed  CAS  Google Scholar 

  9. National Institute of Health. Third Report on the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication 01-3670. Bethesda, MD: National Institutes of Health; 2001.

    Google Scholar 

  10. Haffner SM, Valdez RA, Hazuda HP, et al.: Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992, 41:715–722.

    Article  PubMed  CAS  Google Scholar 

  11. Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683–689.

    Article  PubMed  CAS  Google Scholar 

  12. Trevisan M, Liu J, Bahsas FB, Menotti A: Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. Am J Epidemiol 1998, 148:958–966.

    PubMed  CAS  Google Scholar 

  13. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356–359.

    Article  PubMed  Google Scholar 

  14. Glueck CJ, Papanna R, Wang P, et al.: Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metab Clin Exp 2003, 52:908–915.

    PubMed  CAS  Google Scholar 

  15. Dahlgren E, Johansson S, Lindsted G, et al.: Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992, 57:505–513.

    PubMed  CAS  Google Scholar 

  16. Attia GR, Rainey WE, Carr BR: Metformin directly inhibits androgen production in human theca cells. Fertil Steril 2001, 76:517–524.

    Article  PubMed  CAS  Google Scholar 

  17. Duleba AJ, Pawelczyk LA, Yuen HB, Moon YS: Insulin actions on ovarian steroidogenesis are not modulated by metformin. Hum Reprod 1993, 8:1194–1198.

    PubMed  CAS  Google Scholar 

  18. Velazquez EM, Mendoza S, Hamer T, et al.: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metab Clin Exp 1994, 43:647–654.

    PubMed  CAS  Google Scholar 

  19. Nestler JE, Jakubowicz DJ: Decreases in ovarian cytochrome p450c1alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996, 335:617–623.

    Article  PubMed  CAS  Google Scholar 

  20. Velazquez E, Acosta A, Mendoza SG: Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997, 90:392–395.

    Article  PubMed  CAS  Google Scholar 

  21. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998, 138:269–274.

    Article  PubMed  CAS  Google Scholar 

  22. Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK: Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998, 69:691–696.

    Article  PubMed  CAS  Google Scholar 

  23. Unluhizarci K, Kelestimur F, Bayram F, et al.: The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol 1999, 51:231–236.

    Article  CAS  Google Scholar 

  24. Glueck CJ, Wang P, Fontaine R, et al.: Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 1999, 48:511–519.

    Article  PubMed  CAS  Google Scholar 

  25. Pirwany IR, Yates RWS, Cameron IT, Fleming R: Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhea. Hum Reprod 1999, 14:2963–2968.

    Article  PubMed  CAS  Google Scholar 

  26. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L: Metformin therapy improves hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000, 73:1149–1154.

    Article  PubMed  CAS  Google Scholar 

  27. Moghetti P, Castello R, Negri C, et al.: Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000, 85:139–146. A well-designed study evaluating the effect of metformin in women with PCOS, and attempting to determine predictors of response.

    Article  PubMed  CAS  Google Scholar 

  28. Fleming R, Hopkinson ZE, Wallace AM, et al.: Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab 2002, 87:569–574. The largest, randomized prospective trial evaluating the effect of metformin in women with PCOS.

    Article  PubMed  CAS  Google Scholar 

  29. Dunaif A, Segal KR, Futterweit W, Dobrjansky A: Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989, 38:1165–1174.

    Article  PubMed  CAS  Google Scholar 

  30. Mather KJ, Kwan F, Corenblum B: Hyperinsulinemia in polycystic ovarian syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril 1999, 73:150–156.

    Article  Google Scholar 

  31. Nestler JE, Jakubowicz DJ: Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian p450c17alpha activity and serum androgens. J Clin Endocrinol Metab 1997, 82:4075–4079.

    Article  PubMed  CAS  Google Scholar 

  32. Crave JC, Fimbel S, Lejeune H, et al.: Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995, 80:2057–2062.

    Article  PubMed  CAS  Google Scholar 

  33. Acbay O, Gundogdu S: Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 1996, 65:946–949.

    PubMed  CAS  Google Scholar 

  34. Ehrmann DA, Cavaghan MK, Imperial J, et al.: Effects of Metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997, 82:524–530.

    Article  PubMed  CAS  Google Scholar 

  35. Ng EH, Wat NM, Ho PC: Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum Reprod 2001, 16:1625–1631.

    Article  PubMed  CAS  Google Scholar 

  36. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R: Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998, 338:1876–1880.

    Article  PubMed  CAS  Google Scholar 

  37. Vandermolen DT, Ratts VS, Evans WS, et al.: Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001, 75:310–315.

    Article  PubMed  CAS  Google Scholar 

  38. De Leo V, la Marca A, Ditto A, et al.: Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 1999, 72:282–285.

    Article  PubMed  Google Scholar 

  39. Stadtmauer LA, Toma SK, Riehl RM, Talbert LM: Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of insulin-like growth factors. Fertil Steril 2001, 75:505–509.

    Article  PubMed  CAS  Google Scholar 

  40. Ibanez L, Valls C, Potau N, et al.: Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 2000, 85:3526–3530.

    Article  PubMed  CAS  Google Scholar 

  41. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al.: Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87:524–529.

    Article  PubMed  CAS  Google Scholar 

  42. Regan L, Braude PR, Trembath PL: Influence of past reproductive performance on risk of spontaneous abortion. BMJ 1989, 299:541–545.

    PubMed  CAS  Google Scholar 

  43. Glueck CJ, Phillips H, Cameron D, et al.: Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001, 75:46–52.

    Article  PubMed  CAS  Google Scholar 

  44. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L: Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002, 17:2858–2864.

    Article  PubMed  CAS  Google Scholar 

  45. Coetzee EJ, Jackson WP: Oral hypoglycemics in the first trimester and fetal outcome. S Afr Med J 1984, 65:635–637.

    PubMed  CAS  Google Scholar 

  46. Wild RA, Painter PC, Coulson PB, et al.: Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985, 61:946–951.

    Article  PubMed  CAS  Google Scholar 

  47. Talbott E, Guzick D, Clerici A, et al.: Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995, 15:821–826.

    PubMed  CAS  Google Scholar 

  48. Dahlgren E, Janson PO, Johansson S, et al.: Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril 1994, 61:455–460.

    PubMed  CAS  Google Scholar 

  49. Talbott EO, Zborowski JV, Guzick DS, et al.: Increased PAI-1 levels in women with polycystic ovary syndrome: Evidence for a specific "PCOS" effect independent of age and BMI. Programs and Abstracts of the 40th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, American Heart Association. San Diego, CA; 2000.

  50. Zimmermann S, Phillips RA, Dunaif A, et al.: Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J Clin Endocrinol Metab 1992, 75:508–513.

    Article  PubMed  CAS  Google Scholar 

  51. Talbott EO, Guzick DS, Sutton-Tyrell K, et al.: Evidence for an association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000, 20:2414–2421.

    PubMed  CAS  Google Scholar 

  52. Festa A, D'Agostino RJr, Tracy RP, et al.: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51:1131–1137.

    Article  PubMed  CAS  Google Scholar 

  53. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836–843.

    Article  PubMed  CAS  Google Scholar 

  54. Kelly CC, Lyall H, Petrie JR, et al.: Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001, 86:2453–2455.

    Article  PubMed  CAS  Google Scholar 

  55. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years [no authors listed]. BMJ 1995, 310:83–88.

    Google Scholar 

  56. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:854–865.

  57. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L:Metformin improves lipid profile in hyperinsulinemic women with polycystic ovary syndrome. Paper presented at the 46th Annual Meeting of the Society for Gynecologic Investigation. Toronto, Canada; 1999.

  58. Velazquez EM, Mendoza SG, Wang P, Glueck CJ: Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metab Clin Exp 1997, 46:454–457.

    PubMed  CAS  Google Scholar 

  59. Legro RS: Diabetes prevalence and risk factors in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001, 28:99–109.

    Article  PubMed  CAS  Google Scholar 

  60. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group [no authors listed]. N Engl J Med 2002, 346:393–403. An excellent study identifying metformin as a useful medication for the prevention of type 2 diabetes in patients with insulin resistance. A very interesting finding from this study is that lifestyle interventions are even more beneficial.

  61. Lebovitz HE: Differentiating members of thiazolidine class: a focus on safety. Diabetes Metab Res Rev 2002, 18:S23-S29.

    Article  PubMed  CAS  Google Scholar 

  62. Dunaif A, Scott D, Finegood D, et al.: The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996, 81:3299–3306.

    Article  PubMed  CAS  Google Scholar 

  63. Hasegawa I, Murakawa H, Suzuki M, et al.: Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil Steril 1999, 71:323–327.

    Article  PubMed  CAS  Google Scholar 

  64. Mitwally MF, Kuscu NK, Yalcinkaya TM: High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Hum Reprod 1999, 14:2700–2703.

    Article  PubMed  CAS  Google Scholar 

  65. Azziz R, Ehrmann DA, Legro RS, et al.: Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2001, 86:1626–1632. An excellent study with appropriate design. Although troglitazone is removed from the market, the findings of this study increase our interest in other thiazolidinediones.

    Article  PubMed  CAS  Google Scholar 

  66. Shobokshi A, Shaarawy M: Correction of insulin resistance and hyperandrogenism in polycystic ovarian syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Investig 2003, 10:99–104.

    Article  PubMed  CAS  Google Scholar 

  67. Ghazeeri G, Kutteh WH, Bryer-Ash M, et al.: Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003, 79:562–566.

    Article  PubMed  Google Scholar 

  68. Salzman A, Patel J: Rosiglitazone therapy is not associated with hepatotoxicity. Diabetes 1999, 48:A98.

    Google Scholar 

  69. Romualdi D, Guido M, Ciampelli M, et al.: Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinemic obese patients with polycystic ovarian syndrome. Hum Reprod 2003, 18:1210–1218.

    Article  PubMed  CAS  Google Scholar 

  70. Glueck CJ, Moreira A, Goldenberg N, et al.: Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003, 18:1618–1625.

    Article  PubMed  CAS  Google Scholar 

  71. May L, Lefkowich J, Kram M, Rubin D: Mixed hepatocellular cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002, 136:449–452.

    PubMed  Google Scholar 

  72. Maeda K: Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med 2001, 135:306.

    PubMed  CAS  Google Scholar 

  73. Larner J: Multiple pathways in insulin signaling: fitting the covalent and allosteric puzzle pieces together. Endocr J 1994, 2:167–171.

    CAS  Google Scholar 

  74. Ortmeyer HK, Bodkin NL, Lilley K, et al.: Chiroinositol deficiency and insulin resistance. I. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys. Endocrinology 1993, 132:640–645.

    Article  PubMed  CAS  Google Scholar 

  75. Asplin I, Galasko G, Larner J: Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci U S A 1993, 90:5924–5928.

    Article  PubMed  CAS  Google Scholar 

  76. Nestler JE, Jakubowicz DJ, Reamer P, et al.: Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999, 340:1314–1320.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Yale University School of Medicine, 333 Cedar Street, 06520-8063, New Haven, CT, USA

    Emre Seli MD & Antoni J. Duleba MD

Authors
  1. Emre Seli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antoni J. Duleba MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seli, E., Duleba, A.J. Treatment of PCOS with metformin and other insulin-sensitizing agents. Curr Diab Rep 4, 69–75 (2004). https://doi.org/10.1007/s11892-004-0014-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-004-0014-8

Keywords

Search

Navigation